Acanthamoeba Keratitis Clinical Trial
— REAGIROfficial title:
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial treatment plus cross-linking with rose Bengal (RB-PDT). Patients presenting to one of the Aravind Eye Hospitals in India or to the Federal University of São Paulo ophthalmology clinic in Brazil with either smear or culture positive fungal or acanthamoeba keratitis or smear and culture negative corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be randomized to one of two treatment groups: Group 4, Sham RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT Group 5, RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT.
Status | Recruiting |
Enrollment | 330 |
Est. completion date | July 31, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Presence of smear or culture positive fungal or acanthamoeba ulcer; smear or culture negative ulcer; or any atypical bacteria (such as Nocardia) - Moderate to severe vision loss, defined as Snellen visual acuity of 20/40 (6/12) or worse - Corneal thickness =350 µm, as measured on AS-OCT - Age over 18 years - Basic understanding of the study as determined by the physician - Commitment to return for follow up visits Exclusion Criteria: - Evidence of concomitant infection on exam, gram stain, or confocal microscopy (i.e. herpes, both bacteria and acanthamoeba on gram stain) - Impending or frank perforation at recruitment - Involvement of sclera at presentation - Non-infectious or autoimmune keratitis - History of corneal transplantation - History of intraocular surgery within last three months - Pinhole visual acuity worse than 20/200 in the unaffected eye - Participants who are decisionally and/or cognitively impaired - Presence of demestocele at recruitment |
Country | Name | City | State |
---|---|---|---|
Brazil | Federal University of São Paulo | São Paulo | |
India | Aravind Eye Care System | Madurai | Tamil Nadu |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | Aravind Eye Care System, Federal University of São Paulo, National Eye Institute (NEI), Stanford University |
Brazil, India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Best Spectacle-Corrected Visual Acuity | Best Spectacle-Corrected Visual Acuity | 6 Months | |
Secondary | Best Spectacle-Corrected Visual Acuity | Best Spectacle-Corrected Visual Acuity | 3 Weeks, 3 Months, 12 Months | |
Secondary | Scar Size | Geometric Mean | 3 Weeks, 3 Months, 6 Months 12 Months | |
Secondary | Scar Depth | Geometric Mean | 3 Weeks, 3 Months, 6 Months 12 Months | |
Secondary | Adverse Events | Adverse Events | 12 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02506257 -
Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06332703 -
Acanthamoeba and Artificial Intelligence
|
||
Enrolling by invitation |
NCT03461978 -
Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures
|
N/A | |
Recruiting |
NCT02763605 -
Retrospective Study of Acanthamoebic Keratitis During the Past 10 Years
|
N/A | |
Active, not recruiting |
NCT03484507 -
Parasitic Ulcer Treatment Trial Pilot
|
Phase 2 | |
Completed |
NCT03274895 -
Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
|
Phase 3 | |
Not yet recruiting |
NCT06213649 -
Parasitic Ulcer Treatment Trial
|
Phase 3 |